IP Library Granted Patent US 10,166,295
Granted Patent B2
US 10,166,295 · App. 14/725,883 · Granted Jan 1, 2019

Pegylated OXM variants

Inventors: Udi Eyal Fima (Dvira, IL); Oren Hershkovitz (M.P. Shikmim, IL)
Assignee: OPKO Biologics Ltd.
A61K47/48215A61K38/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,166,295
App. No.
14/725,883
Granted
Jan 1, 2019
Kind
B2
Abstract

A composition which includes oxyntomodulin and polyethylene glycol polymer (PEG polymer) linked via a reversible linker such as 9-fluorenylmethoxycarbonyl (Fmoc) or sulfo-9-fluorenylmethoxycarbonyl (FMS) is disclosed. Pharmaceutical compositions comprising the reverse pegylated oxyntomodulin and methods of using same are also disclosed.

Claims (16)

1. A method for the preparation of an oxyntomodulin (OXM) conjugate represented by the structure of formula II:

wherein R 2 is H or SO 3 H;

said method comprises:

reacting MAL-Fmoc-NHS (R 2 ═H) represented by the following structure:

MAL-FMS-NHS (R 2 ═SO 3 H) represented by the following structure:

with a resin-bound oxyntomodulin of SEQ ID NO:1, wherein the amino side chains of Lys 12 and Lys 30 of said resin-bound oxyntomodulin are each protected by a protecting group, to obtain a resin-bound MAL-Fmoc-protected OXM or a resin-bound MAL-FMS-protected OXM, respectively;

followed by

(b) reaction of the resin-bound MAL-Fmoc-protected OXM or the resin-bound MAL-FMS-protected OXM with sulfhydryl PEG polymer (PEG-SH) and subsequently removing the protecting groups and said resin; or

(c) removal of the protecting group and the resin to provide MAL-Fmoc-OXM and a MAL-FMS-OXM, respectively, and subsequent reaction of the MAL-Fmoc-OXM or the MAL-FMS-OXM with sulfhydryl PEG polymer (PEG-SH);

to yield the structure of formula II, wherein the amino residue of His 1 of said OXM is linked to said Fmoc or FMS.

2. The method of claim 1 , wherein said MAL-FMS-NHS is prepared by mixing MAL-Fmoc-NHS with trifluoroacetic acid and chlorosulfonic acid.

3. The method of claim 2 , wherein MAL-Fmoc-NHS is dissolved in neat trifluoroacetic acid and 6 equivalents of chlorosulfonic acid dissolved in neat trifluoroacetic acid is added to the reaction mixture.

4. The method of claim 1 , wherein said protecting group of said Lys 12 and Lys 30 is 1-[(4,4-dimethyl-2,6-dioxocyclohex-1-ylidine)ethyl]), (ivDde).

5. The method of claim 1 wherein said reaction with said sulfhydryl PEG polymer (PEG-SH) is conducted under a buffer condition of pH between 6 and 6.5.

6. The method of claim 1 , wherein said PEG has a molecular weight in the range of 20,000 Da to 40,000 Da.

7. The method of claim 6 , wherein said PEG has a molecular weight with an average molecular weight of 30,000 Da.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 5, 2018
From: FIMA, UDI EYAL; HERSHKOVITZ, OREN
To: OPKO BIOLOGICS LTD.
Reel/Frame 046272/0310 →
Continuity (10)
Continuation In Part 14405597 · Dec 4, 2014
Continuation In Part 14592641 · Jan 8, 2015
Continuation In Part PCTIL2013050481 · Jun 4, 2013
Continuation In Part PCTIL2013050481 · Jun 4, 2013
Continuation In Part 14725883
Continuation In Part 14123106
Provisional Application 61655367 · Jun 4, 2012
Provisional Application 61492448 · Jun 2, 2011
Provisional Application 61624589 · Apr 16, 2012
Related Publication 20150258208A1 · Sep 17, 2015